

PSM

June 1, 2005

NOTICE TO THE TRADE – DeCA NOTICE 05-102

SUBJECT: Sales Restriction Policy of Product Containing Pseudoephedrine (PSE)

The Defense Commissary Agency (DeCA) has decided to enforce the purchase limit to three packages of product (or multiple similar products) containing PSE.

The U.S. Drug Enforcement Administration (DEA) is asking retailers to limit sales of over-the-counter (OTC) cold, flu, and allergy pills containing pseudoephedrine (PSE) to help control the illegal manufacturing of methamphetamine.

Pseudoephedrine is a safe and effective nasal decongestant. However, the diversion of PSE and PSE containing medicines for the illicit production of methamphetamine is a growing problem within the United States.

Accordingly, we will, as a matter of DeCA policy, treat the purchase of more than three packages of a product (or multiple similar products) containing PSE as a potential abuse of commissary privileges, which must be reported to the installation commander or his/her designee.

The comprehensive Methamphetamine Control Act of 1996 Administered by the U.S. DEA imposes controls over the sale of legitimate nonprescription, OTC cough/cold, allergy/sinus, and asthma medicines that contain the ingredients PSE in combination with other active ingredients.

Point of contact regarding this policy is Ms. Patricia Lepore. She can be reached at 804-734-8267.

/s/

Scott E. Simpson
Chief Operating Officer